Prestige Consumer Healthcare PBH Business Segments
| FY'26 | FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|---|
| Total revenues by Business | |||||
| International OTC Healthcare | $175.13M-1.5% | $177.75M+6.4% | $167.1M+8.5% | $153.95M+29.4% | |
| North American OTC Healthcare | $913.58M-4.8% | $960.01M+0.2% | $958.26M-1.6% | $973.77M+0.6% | |
| Gross Profit by Business | |||||
| International OTC Healthcare | $94.7M-8.3% | $103.32M+8.1% | $95.55M+2.3% | $93.36M+29.8% | |
| North American OTC Healthcare | $500.88M-5.7% | $531.14M+0.4% | $528.9M-0.6% | $531.93M-3.1% | |
| Contribution Margin by Business | |||||
| International OTC Healthcare | $66.77M-13.3% | $77.03M+4.5% | $73.73M+2.1% | $72.23M+35.5% | |
| North American OTC Healthcare | $380.03M-5.4% | $401.71M+1.1% | $397.41M-2.6% | $408M-0.5% | |
| Goodwill, Gross by Business | |||||
| International OTC Healthcare | $125M+1.7% | $122.92M+2.0% | $120.53M-0.1% | $120.7M-5.8% | |
| North American OTC Healthcare | $2.95B+3.7% | $2.85B0.0% | $2.85B0.0% | $2.85B0.0% | |
| Cost of Sales by Business | |||||
| International OTC Healthcare | $80.43M+8.1% | $74.43M+4.0% | $71.55M+18.1% | $60.59M+28.9% | |
| North American OTC Healthcare | $412.7M-3.8% | $428.87M-0.1% | $429.36M-2.8% | $441.84M+5.4% | |
| Goodwill, Impaired, Accumulated Impairment Loss by Business | |||||
| International OTC Healthcare | $6.35M0.0% | $6.35M0.0% | $6.35M0.0% | $6.35M+19.1% | |
| North American OTC Healthcare | $850.06M0.0% | $850.06M0.0% | $850.06M+20.8% | $703.65M+7.5% | |
| Advertising and marketing by Business | |||||
| International OTC Healthcare | $27.94M+6.2% | $26.29M+20.5% | $21.82M+3.2% | $21.14M+13.5% | |
| North American OTC Healthcare | $120.85M-6.6% | $129.43M-1.6% | $131.49M+6.1% | $123.93M-10.7% | |
| Effects of foreign currency exchange rates by Business | |||||
| International OTC Healthcare | $1.63M— | —— | -$441K— | —— | |
| North American OTC Healthcare | -$721K— | $0— | $0— | $0— | |
| Goodwill by Business | |||||
| International OTC Healthcare | $118.65M+1.8% | $116.57M+2.1% | $114.19M-0.1% | $114.36M-6.9% | |
| North American OTC Healthcare | $2.1B+5.2% | $2B0.0% | $2B-6.8% | $2.14B-2.3% | |
| Total revenues by Product | |||||
| Analgesics | $113.94M-3.2% | $117.7M+0.2% | $117.45M-1.5% | $119.26M-0.1% | |
| Cough & Cold | $101.91M-4.1% | $106.21M-10.8% | $119.02M-6.3% | $126.99M+18.6% | |
| Dermatologicals | $125.93M-2.3% | $128.95M-0.1% | $129.1M+4.3% | $123.74M+2.8% | |
| Eye & Ear Care | $142.94M-22.0% | $183.32M+2.2% | $179.42M+4.9% | $171.08M+4.7% | |
| Gastrointestinal | $259.79M+1.5% | $255.94M+10.5% | $231.61M+2.2% | $226.58M+10.8% | |
| Oral Care | $101.05M+6.3% | $95.03M-1.3% | $96.31M-1.4% | $97.63M+0.1% | |
| Other OTC | $15.39M+11.7% | $13.78M+14.6% | $12.03M+8.4% | $11.1M+11.1% | |
| Women's Health | $227.77M-3.8% | $236.83M-1.5% | $240.42M-4.3% | $251.35M-5.0% | |
| Concentration risk, percentage by Product | |||||
| Manufacturers | 60%+2.0pp | 58%-14.0pp | 72%+2.2pp | 69.8%+0.8pp | |
| Manufacturers, United States, Canada and Australia | 21%— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Prestige Consumer Healthcare break its business down?
- Prestige Consumer Healthcare (PBH) reports total revenues by business across 2 parts — International OTC Healthcare and North American OTC Healthcare. Each is extracted from the segment footnotes and tracked over time.
- Where does Prestige Consumer Healthcare's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Prestige Consumer Healthcare's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.